Inhibition of tumor neovascularization is an effective method to achieve metastatic suppression in lung cancer.[201] Antiangiogenic agents widely used to treat lung cancer include vascular endothelial growth factor (VEGF) inhibitors (bevacizumab), recombinant human vascular endothelial inhibitors, and small‐molecule multitargeted tyrosine kinase inhibitors (amilorotinib hydrochloride). Here, VEGFA is linked to lung cancer.